Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Venous thromboembolism (VTE) encompasses deep venous thrombosis and pulmonary embolus, and is
the proximate cause of death in over 100,000 hospitalized patients per year.
This project will critically examine the pharmacokinetics of prophylactic doses of enoxaparin
in surgical patients, and will evaluate how alteration of enoxaparin dose magnitude and
frequency affects peak and trough aFXa levels as well as risk for re-operative hematoma. If
subtherapeutic aFXa levels are observed, the study will design, implement and test a clinical
protocol to optimize post-operative aFXa levels. Although not an explicit Aim, this study
will also provide important preliminary data on VTE rates in surgical patients with in range
and out of range aFXa levels.